The imaging modalities included tau-PET, amyloid-PET, FDG-PET (for quantifying glucose metabolism), resting-fMRI (for neuronal activity at rest), ALS-MRI (for cerebral blood flow), and structural-MRI (for gray matter density). This evidence concerns the gene MAPT and amyotrophic lateral sclerosis.